Greenwich Net Debt To E B I T D A from 2010 to 2024
| GLSI Stock | USD 14.25 0.32 2.20% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.74959605 | Current Value 0.71 | Quarterly Volatility 4.11525922 |
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 K, Interest Expense of 259.6 K or Selling General Administrative of 1.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 21.18. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules.
Greenwich | Net Debt To E B I T D A |
Latest Greenwich Lifesciences' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Greenwich Lifesciences over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Greenwich Lifesciences' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Greenwich Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 1.62 | |
| Coefficient Of Variation | 254.37 | |
| Mean Deviation | 2.42 | |
| Median | 0.000034 | |
| Standard Deviation | 4.12 | |
| Sample Variance | 16.94 | |
| Range | 15.6058 | |
| R-Value | 0.34 | |
| Mean Square Error | 16.13 | |
| R-Squared | 0.12 | |
| Significance | 0.22 | |
| Slope | 0.31 | |
| Total Sum of Squares | 237.10 |
Greenwich Net Debt To E B I T D A History
About Greenwich Lifesciences Financial Statements
Investors use fundamental indicators, such as Greenwich Lifesciences' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 0.75 | 0.71 |
Currently Active Assets on Macroaxis
When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:Check out the analysis of Greenwich Lifesciences Correlation against competitors. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Return On Assets (0.72) | Return On Equity (1.24) |
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.